acmefirewoodis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Which of the studies was he referring to UCLA, Neuroscience Associates, or PharmaNet? It appeared that they "cherry picked" various slides from each of the studies.
The presentation was a major disappointment. They showed data from four different studies and came up with the conclusion that MANF demonstrated "potential benefit" over GDNF.
Dr. Rubinfeld barely had to time to note that he was formerly with Amgen back in the day. Didn't add anything worthwhile.
See you at .05 tomorrow.
p.s. I told you to sell some shares today.
.05 tomorrow.
The bloom is off the rose.
.05 is still a $50,000,000 market cap with a billion shares outstanding.
I suggest you lock in some profits before they evaporate.
Ask someone who bought shares of Amarantus' partner Rainbow Coral (RBCC) at $1.26 a few weeks ago about buying at the top.
Dendreon (DNDN) went to $55.00 with similar short interest and with fewer positive catalysts to drive it there.
European approval plus European partner takes this to $18.00.
IMHO
p.s. Sanofi?
I'm thinking the dump begins when the share volume hits 15,000,000.
Any other guess?
Closes today at .1265. .058 by Friday.
All imho.
p.s. The hype is dying.
.07 tomorrow. Lock in your profits before they evaporate.
1,000,000,000 shares outstanding sooner than you know.
Just saying.
.07 equals a $70,000,000 market cap on a fully diluted basis for a company with three employees and having lost almost $3,000,000 in the first nine months of 2012.
The MANF technology is years and a $1,000,000,000 investment away from having a 1 in 5,000 chance of producing a viable drug.
Place your bet.
.07 by Friday.
Management has 1,000,000,000 shares to work with now.
Did anyone call Gerald and ask him how much Dr. Rubinfeld is being paid for his endorsement?
Someone had posted that the company has paid over $2,000,000 for consulting/advisory services for the first nine months of 2012. Is this correct? The filings aren't very specific as to where the G&A expenditures are going.
Dr. Rubinfeld’s Other Board Position Hasn’t Fared So Well.
Apparently he was given over 1,000,000 shares as compensation for joining Reginicin’s Board of Directors. Seems that a 1,000,000 shares is in his “wheel house”.
http://www.prnewswire.com/news-releases/regenicin-appoints-amgen-co-founder-dr-joseph-rubinfeld-to-board-of-directors-101369434.html
A Good Read
http://www.thestreet.com/story/11579041/1/fda-did-not-approve-regenicin-skin-graft.html?puc=yahoo&cm_ven=YAHOO
.06 by Friday.
Paper profits look good but cash has a lot less downside.
The hype is just about over for now.
GLTA
"At record cash levels, pharmaceutical companies eye acquisitions"
http://www.nj.com/business/index.ssf/2013/01/pharmaceutical_companies_with.html
Sanofi would be the perfect suitor.
ARNA is one press release away from doubling overnight.
Shorts are going to get burned badly here.
DNDN went from $5.00 to $55.00 on just such a short squeeze.
$13.00 by Friday is possible. IMHO. :)
Motley Fool:
Arena's (NASDAQ: ARNA) Belviq has become the first effective, safe and non-addictive obesity drug. According to a report from the Drug Enforcement Administration (DEA), Belviq should be classified as a Schedule IV drug, which means it has a low risk for abuse. The DEA's drug classification is required before a drug can be sold. This is great news for obese people who want easy access to Belviq. This is also great news for investors who want to see the commercial success of Belviq.
Arena's February 2013 commercial launch of Belviq is around the corner. Its partner Eisai is moving aggressively to prepare for its own role. The schedule IV classification allows physicians to prescribe Belviq to patients through local pharmacies for a three-month supply. Eisai argued that exceptional circumstances exist related to the obesity epidemic, and that a final order should be granted at the end of the notice period (Jan. 18). This final order will likely be granted, and Belviq will likely be available in local pharmacies in the first week of February 2013. Eisai already has a sales force in place which will market to physicians and educate them about this revolutionary weight management treatment.
Eisai has confirmed that Belviq is being loaded into drug store databases at major pharmacies in preparation for distribution. Major group and individual health insurance plans have already begun to cover Belviq, with Aetna and Blue Cross also planning coverage. Arena's CEO Jack Lief has hinted that Belviq will be priced under $4 a day for the two-pill daily dose. European approval is expected in early 2013. Arena has not yet finalized a partner in Europe as it will be in a better position to negotiate after this approval has been received.
Can someone please call Gerald and ask him how much Dr. Rubinfeld is being paid for his endorsement?
Someone had posted that the company has paid over $2,000,000 for consulting/advisory services for the first nine months of 2012. Is this correct?
Dr. Rubinfeld’s Other Board Position Hasn’t Fared So Well.
Apparently he was given over 1,000,000 shares as compensation for joining Reginicin’s Board of Directors. Seems that a 1,000,000 shares is in his “wheel house”.
http://www.prnewswire.com/news-releases/regenicin-appoints-amgen-co-founder-dr-joseph-rubinfeld-to-board-of-directors-101369434.html
A Good Read
http://www.thestreet.com/story/11579041/1/fda-did-not-approve-regenicin-skin-graft.html?puc=yahoo&cm_ven=YAHOO
It's interesting to see so many posts from individuals claiming to own millions of shares that they supposebly purchased below a penny or two trying to convince others that buying now makes perfect sense.
The company lost almost $3,000,000 in the first nine months of 2012 with only three employees.
The company increased the number of authorized shares to 1,000,000,000 recently and the "pumpers" would have you believe that management has no intent to issue them.
The company delayed the release of the MANF data by almost three weeks after having the MJFF challenge previous data back in November.
I may be wrong but I think .05 would be a reasonable price to place a bet on this penny stock.
All imho.
If you think others should buy it now just think what a great deal it will be for them to buy at .05 in a few days.
How much compensation did the company pay Dr. Rubinfeld to join its Board of Directors?
Could you please call Gerald and ask him.
Based on other's posts it appears that he is readily available to answer questions from shareholders.
All imho.
GLTA
Remember all the hype and expectations on the board that the data would be released on or before December 22?
Why delay it for almost three weeks and then promote Dr. Rubinfeld with his previous ties to Amgen as being the keynote presenter at the One Med Forum?
Didn't make sense to delay the results.
All imho.
p.s. I notice the RBCC bagholders at $1.26 aren't doing much better today.
"set up big conferences"???
For $5,450 just about any bio-tech can participate.
http://www.onemedplace.com/forum/company_registration.php
.05 by Friday seems about right.
"MJFF is not considering additional funding to Amarantus at this time."
http://www.prnewswire.com/news-releases/correction-amarantus-biosciences-updates-shareholders-on-timing-of-michael-j-fox-foundation-grant-data-release-178201671.html
Interesting that the data that was expected in December was delayed almost three weeks.
Just saying.
All imho.
This can't be good news.
Questionable data?
Just saying.
I expect the share price will take at least a 50% hit within two weeks from this week's high.
Most of the newbies will lose money buying this week.
It's the land of penny stocks.
GLTA
"MJFF is not considering additional funding to Amarantus at this time."
http://www.prnewswire.com/news-releases/correction-amarantus-biosciences-updates-shareholders-on-timing-of-michael-j-fox-foundation-grant-data-release-178201671.html
Interesting that the data that was expected in December was delayed almost three weeks.
Just saying.
All imho.
I especially liked the A.F. article which contained the following:
Regenicin CEO Randy McCoy, in a phone interview, claims FDA will allow PermaDerm to be approved and marketed without filing a formal approval application. When his claim was challenged, McCoy got mad and hung up the phone.
PermaDerm has been in development for more than 20 years, during which U.S. regulators have issued multiples warning letters due to unreliable clinical data and improper testing procedures, according to a 2011 report by BioPharmCatalyst.
Regenicin is close to insolvency. The company, which is headquartered in the home of its CEO, finished the first quarter with only $36,000 in cash on hand. Since then, Regenicin has survived on high-interest loans from certain unnamed individuals, according to SEC filings.
--Written by Adam Feuerstein in Boston.
I assume that since Dr. Rubinfeld apparently accepted over a million shares to join the company's Board of Directors (sound familar?)and promote the company's products that the company is going to be worth billions in the future.
All imho.
"Selling at the top is just as important as buying at the bottom."
I expect that the share price will drop at least 50% from this week's high within two weeks so it's very important to try to time the top.
"Pigs get fat and hogs get slaughtered."
GLTA
Is too much emphasis being placed on Dr. Rubinfeld's association with the company?
Dr. Rubinfeld’s Other Board Position Hasn’t Fared So Well.
Apparently he was given over 1,000,000 shares as compensation for joining Reginicin’s Board of Directors. Seems that a 1,000,000 shares is in his “wheel house”.
http://www.prnewswire.com/news-releases/regenicin-appoints-amgen-co-founder-dr-joseph-rubinfeld-to-board-of-directors-101369434.html
A Good Read
http://www.thestreet.com/story/11579041/1/fda-did-not-approve-regenicin-skin-graft.html?puc=yahoo&cm_ven=YAHOO
p.s. Let's hope that Adam stays away from researching AMBS and especially its partner Rainbow Coral (RBCC). Has anyone e-mailed or twittered A.F. to get his comment on AMBS?
Adam Feuerstein@adamfeuerstein
All imho.
Designating an Orphan Product: Drugs and Biologics
The Orphan Drug Act (ODA) provides for granting special status to a product to treat a rare disease or condition upon request of a sponsor. The combination of the product to treat the rare disease or condition must meet certain criteria. This status is referred to as orphan designation. Orphan designation qualifies the sponsor of the product for the tax credit and marketing incentives of the ODA. A marketing application for a prescription drug product that has been designated as a drug for a rare disease or condition is not subject to a prescription drug user fee unless the application includes an indication for other than a rare disease or condition.
In order for a sponsor to obtain orphan designation for a drug or biological product, an application must be submitted to OOPD, and the designation approved. The approval of an application for orphan designation is based upon the information submitted by the sponsor. A drug that has obtained orphan designation is said to have "orphan status." Each designation request must stand on its own merit. Sponsors requesting designation of the same drug for the same indication as a previously designated product must submit their own data in support of their designation request. The approval of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval. Safety and efficacy of a compound must be established through adequate and well-controlled studies.[color=red][/color]
When have I bashed the stock?
Most of my post contain links that provide additional information to the reader. It's up to them to draw their own conclusion(s) as to any impact the information has on the future share price.
When I state that the vast number of penny stock companies lose money as do the investors that buy their shares that is not bashing that is a fact.
Stating that the company lost almost $3,000,000 in the first nine months of 2012 with only three employees is a fact.
Posting a link that stated that the Michael J. Fox Foundation disputed the company's comments about the MANF study data wasn't bashing.
Suggesting that individuals go on Google maps to view the office location for Rainbow Coral's (RBCC) office location in Florida isn't bashing. It appears to be a very nice neighborhood.
Sometimes a little more information will help anyone considering buying at the current price a bit more aware of the risks involved considering the recent run-up in the share price.
If I were bashing the stock I'd list another 10-15 items of concern.
Up to $1.7 billion and 15 years.
http://www.pdpipeline.org/2011/Eithics/navagating/regulatory.htm
The only realistic hope to make any substantial profit here is a takeover which currently would be in the .33 range and headed lower as dilution occurs.
Possibly the company's partner, Rainbow Coral (RBCC, could help to finance Amarantus by developing a few more coral reefs.
How many companies have Dr. Rubinfeld on their Board of Directors?
One of Dr. Rubinfeld’s Other Board Position Hasn’t Fared So Well.
Apparently he was given over 1,000,000 shares as compensation for joining Reginicin’s Board of Directors. Seems that a 1,000,000 shares is in his “wheel house”.
http://www.prnewswire.com/news-releases/regenicin-appoints-amgen-co-founder-dr-joseph-rubinfeld-to-board-of-directors-101369434.html
A Good Read
http://www.thestreet.com/story/11579041/1/fda-did-not-approve-regenicin-skin-graft.html?puc=yahoo&cm_ven=YAHOO
p.s. Let's hope that Adam stays away from researching AMBS and especially its partner Rainbow Coral (RBCC). Has anyone e-mailed or twittered A.F. to get his comment on AMBS?
Adam Feuerstein@adamfeuerstein
All imho.
Dr. Rubinfeld’s Other Board Position Hasn’t Fared So Well.
Apparently he was given over 1,000,000 shares as compensation for joining Reginicin’s Board of Directors. Seems that a 1,000,000 shares is in his “wheel house”.
http://www.prnewswire.com/news-releases/regenicin-appoints-amgen-co-founder-dr-joseph-rubinfeld-to-board-of-directors-101369434.html
A Good Read
http://www.thestreet.com/story/11579041/1/fda-did-not-approve-regenicin-skin-graft.html?puc=yahoo&cm_ven=YAHOO
p.s. Let's hope that Adam stays away from researching AMBS and especially its partner Rainbow Coral (RBCC). Has anyone e-mailed or twittered A.F. to get his comment on AMBS?
Adam Feuerstein@adamfeuerstein
All imho.
I don't blame you for not answering the question as you know that is shows GDNF performed better.
If you conduct enough studies eventually a standard bell shape distribution will occur and you might find one that supports your hypothesis. It depends if you pick the right eight rats.
I wish I were as smart as a medical student and then I could possibly grasp these complicated medical concepts.
Since you're a medical student why don't you explain to the board what the following chart from the 2009 study comparing MANF to GDNF indicates:
http://www.jneurosci.org/content/29/30/9651/F4.expansion.html
How much does Dr. Rubinfeld charge to be on a company's board of directors?
http://www.prnewswire.com/news-releases/regenicin-appoints-amgen-co-founder-dr-joseph-rubinfeld-to-board-of-directors-101369434.html
Note how similar his comment are.
Since then I've done some additional due diligence:
After finding out about the increase in the number of authorized shares to 1,000,000,000 and that the preferred shares will convert to over 200,000,000 shares.
Plus finding the results of the 2009 study which showed very little difference between GDNF and MANF.
Researching Rainbow Coral Corporation (RBCC)and it's questionable ability to contribute any value to the company as a partner.
Noting that the company paid to have what I believe to be bogus "short share" announcements released on a monthly basis for six months.
Plus the fact that the current MANF study which was expected to be released on December 22 was delayed almost three weeks.
Also noting the number of penny stock sites that have been "promoting" AMBS over the last six weeks.
Obviously everyone that reads anything posted on here is intelligent enough to make their own decision.
I have to agree with your assessment. Makes someone wonder what the connection was that brought the two companies together. On some level it raises some question as to Gerald's decision making abilities.
We will probably never know the "full story".
However my intent was to point out what can happen when investors buy based on the hype. To me a 75% loss is substantial.
I appreciate the fact that many individuals posting on the board bought AMBS shares below a penny or two and have very little downside risk at the current share price.
Anyone wanting to take the risk at the current share price has to be convinced that there is legitimate upside potential.
The company did increase the number of authorized shares to 1,000,000,000 in November. Typically with penny stocks when that happens eventually they are all sold.
Due diligence is always a good starting point.
.06-.08 by Friday would be a great way to start the year.
Good revenue numbers and a solid overview of the company's expansion plans could easily move it much higher.
Good luck to all the "BONZ" faithful both old and new.
Anyone that was waiting to buy below .015 before the move higher has missed the opportunity to buy at the bottom one more time.
The probability is high that this will hit .05 before it hits .30.
Differing opinions is what makes a market.
AMBS has been "pumped" on a lot of penny stock boards over the last three weeks with high expectations for tomorrow's presentation.
Sometimes reality falls short of expectations.
Look what has happened to the share price of AMBS's partner, Rainbow Coral (RBCC). It hit $1.26 on the "pump" and subsequently has fallen almost 75% to close at .30 on Friday and is probably headed to .10.
Penny stocks are volatile. Typically a few investors will do very well with the majority of investors losing money.
Never invest more money in any stock than you can afford to lose.
All IMHO.
Fair value "if" a buyout offer were made today is .33.
All the talk about $1.00 or $2.00 is "hog wash".
IMHO
The company authorized 1,000,000,000 shares in November because management believes it will need them.
Expecting more volatility this week.
Place a few limit buy orders below .07 and they may get filled.
GLTA
According to the company's profile the company only has two employees. Use google maps to view the company's office location.
Rainbow Coral Corp.
291 LaCosta Road
Nokomis, FL 34275
Houston does have some newer apartment complexes that offer a location near a "biotech complex" at a reasonable monthly rent.
In regards to the following statement I think the companies listed aren't too concerned about competition from Rainbow Coral.
"Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ: CELG), Cardinal Health, Inc. (NYSE: CAH), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY)."
Wasn't the current C.E.O. of Rainbow Coral the former head of the company that promoted the "World Series of Golf" eight or nine years ago? Does Gerald play golf?
p.s. I think AMBS will hit .07 or lower on Tuesday.
IMHO.